Identification and characterization of persistent human erythrovirus infection in blood donor samples

被引:137
作者
Candotti, D
Etiz, N
Parsyan, A
Allain, JP
机构
[1] Natl Blood Serv, Cambridge Blood Ctr, Cambridge CB2 2PT, England
[2] Univ Cambridge, Dept Haematol, Div Transfus Med, Cambridge, England
[3] Refik Saydam Hyg Ctr, Dept Virol, Ankara, Turkey
关键词
D O I
10.1128/JVI.78.22.12169-12178.2004
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The presence of human erythrovirus DNA in 2,440 blood donations from the United Kingdom and sub-Saharan Africa (Ghana, Malawi, and South Africa) was screened. Sensitive qualitative and real-time quantitative PCR assays revealed a higher prevalence of persistent infection with the simultaneous presence of immunoglobulin G (IgG) and viral DNA (0.55 to 1.3%) than previously reported. This condition was characterized by a low viral load (median, 558 IU/ml; range, 42 to 135,000 IU/ml), antibody-complexed virus, free specific IgG, and potentially infectious free virus. Human erythrovirus genotype 1 (formerly parvovirus B19) was prevalent in the United Kingdom, Malawi, and South Africa. In contrast, only human erythrovirus genotype 3 (erythrovirus variant V9) was prevalent in Ghana. Genotype 3 had considerable genetic diversity, clustering in two probable subtypes. Genotype 1-based antibody assays failed to detect 38.5% of Ghanaian samples containing antibodies to genotype 3 virus but did not fail to detect cases of persistent infection. This study indicates a potential African origin of genotype 3 human erythrovirus and considerable shortcomings in the tools currently used to diagnose erythrovirus infection.
引用
收藏
页码:12169 / 12178
页数:10
相关论文
共 50 条
  • [1] The risk of hepatitis B virus infection by transfusion in Kumasi, Ghana
    Allain, JP
    Candotti, D
    Soldan, K
    Sarkodie, F
    Phelps, B
    Giachetti, C
    Shyamala, V
    Yeboah, F
    Anokwa, M
    Owusu-Ofori, S
    Opare-Sem, O
    [J]. BLOOD, 2003, 101 (06) : 2419 - 2425
  • [2] Large-scale screening for human parvovirus B19 DNA by PCR: Application to the quality control of plasma for fractionation
    Aubin, JT
    Defer, C
    Vidaud, M
    Montreuil, MM
    Flan, B
    [J]. VOX SANGUINIS, 2000, 78 (01) : 7 - 12
  • [3] Parvovirus B19 transmission by heat-treated clotting factor concentrates
    Blümel, J
    Schmidt, I
    Effenberger, W
    Seitz, H
    Willkommen, H
    Brackmann, HH
    Löwer, J
    Eis-Hübinger, AM
    [J]. TRANSFUSION, 2002, 42 (11) : 1473 - 1481
  • [4] Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen:: Clinically significant or purely "occult"?
    Bréchot, C
    Thiers, V
    Kremsdorf, D
    Nalpas, B
    Pol, S
    Paterlini-Bréchot, P
    [J]. HEPATOLOGY, 2001, 34 (01) : 194 - 203
  • [5] Brown Kevin E., 2001, Transfusion (Bethesda), V41, P130, DOI 10.1046/j.1537-2995.2001.41010130.x
  • [6] Multiplex real-time quantitative RT-PCR assay for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus type 1
    Candotti, D
    Temple, J
    Owusu-Ofori, S
    Allain, JP
    [J]. JOURNAL OF VIROLOGICAL METHODS, 2004, 118 (01) : 39 - 47
  • [7] Evaluation of a transcription-mediated ampliftication-based HCV and HIV-1 RNA duplex assay for screening individual blood donations: a comparison with a minipool testing system
    Candotti, D
    Richetin, A
    Cant, B
    Temple, J
    Sims, C
    Reeves, I
    Barbara, JAJ
    Allain, JP
    [J]. TRANSFUSION, 2003, 43 (02) : 215 - 225
  • [8] Candotti D, 2001, J MED VIROL, V65, P1, DOI 10.1002/jmv.1093
  • [9] THE PREVALENCE OF ANTIBODY TO HUMAN PARVOVIRUS-B19 IN ENGLAND AND WALES
    COHEN, BJ
    BUCKLEY, MM
    [J]. JOURNAL OF MEDICAL MICROBIOLOGY, 1988, 25 (02) : 151 - 153
  • [10] The VP1-unique region of parvovirus B19: amino acid variability and antigenic stability
    Dorsch, S
    Kaufmann, B
    Schaible, U
    Prohaska, E
    Wolf, H
    Modrow, S
    [J]. JOURNAL OF GENERAL VIROLOGY, 2001, 82 : 191 - 199